Physician profile
Alta Maness
NPI 1639514649
$75,092.19
in general payments reported to CMS, 2019-2025
12 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $300 · 2023: $22K · 2024: $13K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Consulting Fee: $15K · Travel and Lodging: $8,208 · Food and Beverage: $7,870 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,534.00 |
| Consulting Fee | $14,672.50 |
| Travel and Lodging | $8,208.09 |
| Food and Beverage | $7,869.92 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $41,021.48 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $12,987.01 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $8,629.05 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $6,532.76 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Alkermes, INC. | $4,360.12 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Janssen Scientific Affairs, LLC | $1,125.00 | 2023 | Invega Sustenna, Invega Trinza, Invega |
| Lundbeck LLC | $133.86 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $129.07 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $124.74 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.40 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2023 | |
| Almatica Pharma LLC | $13.60 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alta Maness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.